1
|
Oncel S, Safratowich BD, Lindlauf JE, Liu Z, Palmer DG, Briske-Anderson M, Zeng H. Efficacy of Butyrate to Inhibit Colonic Cancer Cell Growth Is Cell Type-Specific and Apoptosis-Dependent. Nutrients 2024; 16:529. [PMID: 38398853 PMCID: PMC10892417 DOI: 10.3390/nu16040529] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2023] [Revised: 02/07/2024] [Accepted: 02/09/2024] [Indexed: 02/25/2024] Open
Abstract
Increasing dietary fiber consumption is linked to lower colon cancer incidence, and this anticancer effect is tied to elevated levels of short-chain fatty acids (e.g., butyrate) because of the fermentation of fiber by colonic bacteria. While butyrate inhibits cancer cell proliferation, the impact on cancer cell type remains largely unknown. To test the hypothesis that butyrate displays different inhibitory potentials due to cancer cell type, we determined half-maximal inhibitory concentrations (IC50) of butyrate in HCT116, HT-29, and Caco-2 human colon cancer cell proliferation at 24, 48, and 72 h. The IC50 (mM) butyrate concentrations of HCT116, HT-29, and Caco-2 cells were [24 h, 1.14; 48 h, 0.83; 72 h, 0.86], [24 h, N/D; 48 h, 2.42; 72 h, 2.15], and [24 h, N/D; 48 h, N/D; 72 h, 2.15], respectively. At the molecular level, phosphorylated ERK1/2 and c-Myc survival signals were decreased by (>30%) in HCT116, HT-29, and Caco-2 cells treated with 4 mM butyrate. Conversely, butyrate displayed a stronger potential (>1-fold) for inducing apoptosis and nuclear p21 tumor suppressor in HCT116 cells compared to HT-29 and Caco-2 cells. Moreover, survival analysis demonstrated that a cohort with high p21 gene expression in their colon tissue significantly increased survival time compared to a low-p21-expression cohort of colon cancer patients. Collectively, the inhibitory efficacy of butyrate is cell type-specific and apoptosis-dependent.
Collapse
Affiliation(s)
- Sema Oncel
- USDA-ARS Grand Forks Human Nutrition Research Center, Grand Forks, ND 58203, USA; (S.O.); (B.D.S.); (J.E.L.); (D.G.P.); (M.B.-A.)
| | - Bryan D. Safratowich
- USDA-ARS Grand Forks Human Nutrition Research Center, Grand Forks, ND 58203, USA; (S.O.); (B.D.S.); (J.E.L.); (D.G.P.); (M.B.-A.)
| | - James E. Lindlauf
- USDA-ARS Grand Forks Human Nutrition Research Center, Grand Forks, ND 58203, USA; (S.O.); (B.D.S.); (J.E.L.); (D.G.P.); (M.B.-A.)
| | - Zhenhua Liu
- School of Public Health and Health Sciences, University of Massachusetts, Amherst, MA 01003, USA;
| | - Daniel G. Palmer
- USDA-ARS Grand Forks Human Nutrition Research Center, Grand Forks, ND 58203, USA; (S.O.); (B.D.S.); (J.E.L.); (D.G.P.); (M.B.-A.)
| | - Mary Briske-Anderson
- USDA-ARS Grand Forks Human Nutrition Research Center, Grand Forks, ND 58203, USA; (S.O.); (B.D.S.); (J.E.L.); (D.G.P.); (M.B.-A.)
| | - Huawei Zeng
- USDA-ARS Grand Forks Human Nutrition Research Center, Grand Forks, ND 58203, USA; (S.O.); (B.D.S.); (J.E.L.); (D.G.P.); (M.B.-A.)
| |
Collapse
|
2
|
Gu C, Tang L, Hao Y, Dong S, Shen J, Xie F, Han Z, Luo W, He J, Yu L. Network pharmacology and bioinformatics were used to construct a prognostic model and immunoassay of core target genes in the combination of quercetin and kaempferol in the treatment of colorectal cancer. J Cancer 2023; 14:1956-1980. [PMID: 37497415 PMCID: PMC10367918 DOI: 10.7150/jca.85517] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2023] [Accepted: 06/18/2023] [Indexed: 07/28/2023] Open
Abstract
Purpose: CRC is a malignant tumor seriously threatening human health. Quercetin and kaempferol are representative components of traditional Chinese medicine (TCM). Previous studies have shown that both quercetin and kaempferol have antitumor pharmacological effects, nevertheless, the underlying mechanism of action remains unclear. To explore the synergy and mechanism of quercetin and kaempferol in colorectal cancer. Methods: In this study, network pharmacology, and bioinformatics are used to obtain the intersection of drug targets and disease genes. Training gene sets were acquired from the TCGA database, acquired prognostic-related genes by univariate Cox, multivariate Cox, and Lasso-Cox regression models, and validated in the GEO dataset. We also made predictions of the immune function of the samples and used molecular docking to map a model for binding two components to prognostic genes. Results: Through Lasso-Cox regression analysis, we obtained three models of drug target genes. This model predicts the combined role of quercetin and kaempferol in the treatment and prognosis of CRC. Prognostic genes are correlated with immune checkpoints and immune infiltration and play an adjuvant role in the immunotherapy of CRC. Conclusion: Core genes are regulated by quercetin and kaempferol to improve the patient's immune system and thus assist in the treatment of CRC.
Collapse
Affiliation(s)
- Chenqiong Gu
- Department of Biochemistry and Molecular Biology, School of Medicine, Jinan University, Guangzhou, 510632, Guangdong, P. R. China
- Central Laboratory of Panyu Central Hospital, Guangzhou, 511400, Guangdong, P.R. China
| | - LinDong Tang
- Department of Biochemistry and Molecular Biology, School of Medicine, Jinan University, Guangzhou, 510632, Guangdong, P. R. China
| | - Yinghui Hao
- Department of Biochemistry and Molecular Biology, School of Medicine, Jinan University, Guangzhou, 510632, Guangdong, P. R. China
- Central Laboratory of Panyu Central Hospital, Guangzhou, 511400, Guangdong, P.R. China
| | - Shanshan Dong
- Department of Biochemistry and Molecular Biology, School of Medicine, Jinan University, Guangzhou, 510632, Guangdong, P. R. China
| | - Jian Shen
- Central Laboratory of Panyu Central Hospital, Guangzhou, 511400, Guangdong, P.R. China
| | - FangMei Xie
- Central Laboratory of Panyu Central Hospital, Guangzhou, 511400, Guangdong, P.R. China
| | - ZePing Han
- Central Laboratory of Panyu Central Hospital, Guangzhou, 511400, Guangdong, P.R. China
| | - WenFeng Luo
- Central Laboratory of Panyu Central Hospital, Guangzhou, 511400, Guangdong, P.R. China
| | - JinHua He
- Central Laboratory of Panyu Central Hospital, Guangzhou, 511400, Guangdong, P.R. China
| | - Li Yu
- Department of Biochemistry and Molecular Biology, School of Medicine, Jinan University, Guangzhou, 510632, Guangdong, P. R. China
| |
Collapse
|